Clinical Trials Browser

Phase 1/2 × Recruiting × Adenocarcinoma × Clear all

NCT04300556 2026-06-04

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

Phase 1/2 Recruiting

BreastGynecologicThoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT07488676 2026-06-04

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

Phase 1/2 Recruiting

GastrointestinalThoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Cholangiocarcinoma, Small Cell Lung Carcinoma

NCT03093116 2026-05-27

TRIDENT-1

Phase 1/2 Recruiting

500 enrolled 2 FDA

EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

Adenocarcinoma, Bronchial Neoplasms, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Colonic Diseases, Colonic Neoplasms, Digestive System Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Sarcoma, Thoracic Neoplasms, Thyroid Diseases, Thyroid Neoplasms, Neuroectodermal Tumors, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT05922930 2026-05-06

Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer

Phase 1/2 Recruiting

GastrointestinalGynecologic

Adenocarcinoma, Ovarian Neoplasms, Pancreatic Neoplasms

NCT07182279 2026-03-09

Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer

Phase 1/2 Recruiting

Adenocarcinoma, Prostatic Neoplasms

NCT04605913 2026-02-25

Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC

Phase 1/2 Recruiting

Gastrointestinal

Adenocarcinoma, Pancreatic Neoplasms

NCT07363382 2026-01-23

The Value of GRPR PET Imaging for Diagnosis and Staging in Prostate Cancer

Phase 1/2 Recruiting

Adenocarcinoma, Prostatic Neoplasms

NCT06782932 2025-12-03

Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer

Phase 1/2 Recruiting

Gastrointestinal

Adenocarcinoma, Carcinoma, Pancreatic Neoplasms

NCT06759064 2025-11-19

IPIZA

Phase 1/2 Recruiting

Gastrointestinal

Adenocarcinoma, Ascites, Stomach Neoplasms

NCT06800313 2025-10-16

A Study of HLD-0915 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Phase 1/2 Recruiting

Adenocarcinoma, Prostatic Neoplasms

NCT07209865 2025-10-07

68Ga-P16-093 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI

Phase 1/2 Recruiting

Adenocarcinoma, Prostatic Neoplasms

NCT05116072 2025-09-25

TPIAT-01

Phase 1/2 Recruiting

Adenocarcinoma

NCT06532799 2024-11-12

BAH250

Phase 1/2 Recruiting

Gastrointestinal

Adenocarcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT05101356 2024-05-21

A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma

Phase 1/2 Recruiting

Adenocarcinoma, Neoplasm Metastasis